GL
GLUE.O
—
NASDAQ
Biotechnology
Glue.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-43,8 %
ROE
-16,6 %
Net margin
-31,2 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$22,68
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Monte Rosa Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific product details and revenue-generating activities are not disclosed in the available data.
Business. Monte Rosa Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific product details and revenue-generating activities are not disclosed in the available data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
American Century Investment Management, Inc.
largest disclosed fund holder
Profitability→
-16,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to GLUE.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Monte Rosa Therapeutics Inc operates in the biotechnology sector within the Health Care industry, though specific product details and revenue-generating activities are not disclosed in the available data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDThe company maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. Total equity stands at $233.1 million, supported by cash and equivalents of $129.9 million. This liquidity position is adequate for near-term operations, as indicated by the low liquidity risk assessment. The absence of debt eliminates interest coverage risks, but the company relies entirely on equity financing to fund its operations.
Profitability metrics reflect a pre-commercial or early-stage development phase, with a net loss of $38.6 million and an operating loss of $54.2 million. Return on equity is negative at -16.6%, and return on assets is -8.6%. These figures are consistent with biotechnology firms investing heavily in research and development before achieving significant commercial revenue. The operating cash flow is negative at -$22.8 million, indicating ongoing cash burn.
Revenue generation is limited, with total revenue reported at $123.7 million. Specific segment or geographic breakdowns are not provided in the available data, preventing an analysis of revenue concentration or diversification. The lack of detailed segment data suggests that revenue may be derived from a single primary activity or that the company is in a transitional phase regarding its reporting structure.
Growth trajectory analysis is constrained by the absence of historical period data. Without multi-year revenue or net income trends, it is not possible to assess the consistency or acceleration of the company's financial performance. The current snapshot provides a static view of the company's financial health but lacks the longitudinal data necessary for trend analysis.
Risk factors are assessed as low for both liquidity and dilution. The low dilution risk suggests that there are no immediate plans for significant equity issuance that would materially impact existing shareholders. However, the negative cash flow and operating losses imply a continued need for capital, which could lead to future dilution if not managed through debt or strategic partnerships.
Recent events include a reconciler enqueue action for Monte Rosa Therapeutics Inc, indicating administrative processing rather than a significant business development. No other notable news, filing, or transcript observations are present in the available data. The lack of recent material events suggests a period of operational stability or quietness in public disclosures.
Key takeaways
- Zero debt and strong cash position of $129.9 million provide a solid liquidity buffer.
- Significant operating losses of $54.2 million highlight the pre-commercial nature of the business.
- Low dilution risk indicates no immediate pressure for equity financing.
- Lack of historical data prevents assessment of growth trends and profitability trajectory.
- Revenue of $123.7 million is present but lacks segment or geographic detail.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$15,49
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$233.1M
Net cashⓘ
$129.9M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-8.6%
ROEⓘ
-16.6%
Cash conversionⓘ
59.0%
CapEx / revenueⓘ
3.8%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy3
Buy6
Hold0
Sell0
Strong sell0
12-month price target$35,60 · Median $37,00
Low $29,00High $40,00
Operating income · consensus-204,6M USD
EPS surprise
+72,5 %
reported vs consensus · beat
Revenue surprise
+178,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$29,00
Mean$35,60
Median$37,00
High$40,00
Spot$15,49
+129.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-43,8 %Above median
Net Margin-31,2 %Above median
ROE-16,6 %Above median
Capex / Rev3,8 %Above median
D/E0,00Above median
Cash Conv0,59Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 75 940 sh17 exercises · 8 grants12 insiders
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 4 351 @ $3,98exercise · 2026-07-15
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 6 000 @ $6,14exercise · 2026-07-06
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 5 407 @ $13,41exercise · 2026-06-30
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 6 000 @ $7,56exercise · 2026-06-29
- Director · Stock Option (Right to Buy) → Common StockDisposed 10 000 @ $4,16exercise · 2026-06-29
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 30 000 @ $7,56exercise · 2026-06-24
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 6 000 @ $7,56exercise · 2026-06-23
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 175 @ $3,98exercise · 2026-06-23
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $6,14exercise · 2026-06-23
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 176 @ $3,98exercise · 2026-06-17
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $6,14exercise · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 25 800 @ $17,10grant · 2026-06-11
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 6 000 @ $6,14exercise · 2026-05-29
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 175 @ $3,98exercise · 2026-05-27
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 176 @ $3,98exercise · 2026-05-22
- Director · Stock Option (Right to Buy) → Common StockDisposed 10 000 @ $4,16exercise · 2026-05-21
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 19 500 @ $16,93grant · 2026-04-06
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockDisposed 536 @ $13,41exercise · 2026-03-02
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockDisposed 25 164 @ $13,41exercise · 2026-02-27
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Monte Rosa Therapeutics, Inc. Market data — financials · 2026-07-31
- reconciler_enqueue (reconciler) on GLUE.O · 2026-07-31
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$46M
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,01 %$11M
- Institutional Investor · as of 2026-03-310,01 %$11M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$55M
- Investment Managers · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$25M
- Investment Managers · as of 2026-03-310,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$51M
- Investment Managers · as of 2026-03-310,00 %$11M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Markus WarmuthPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 26 sellsnet -$3,5M9 insiders · last 365d
- Director, President & CEO · Common StockSold 9 500 @ $23,18$220K · 2026-07-16
- Chief Operating Officer · Common StockSold 4 351 @ $23,38$102K · 2026-07-15
- Chief Operating Officer · Common StockOther 4 351 @ $3,98$17K · 2026-07-15
- Chief Scientific Officer · Common StockSold 400 @ $24,13$10K · 2026-07-06
- Chief Scientific Officer · Common StockOther 6 000 @ $6,14$37K · 2026-07-06
- Chief Scientific Officer · Common StockSold 5 600 @ $23,25$130K · 2026-07-06
- Director · Common StockOther 15 000 · 2026-07-01
- Director · Common StockOther 1 000 000 · 2026-07-01
- Chief Medical Officer · Common StockSold 5 407 @ $24,50$132K · 2026-06-30
- Chief Medical Officer · Common StockOther 5 407 @ $13,41$73K · 2026-06-30
- Chief Medical Officer · Common StockSold 6 000 @ $22,95$138K · 2026-06-29
- Director · Common StockOther 10 000 @ $4,16$42K · 2026-06-29
- Director · Common StockSold 10 000 @ $23,11$231K · 2026-06-29
- Chief Medical Officer · Common StockOther 6 000 @ $7,56$45K · 2026-06-29
- Chief Medical Officer · Common StockOther 30 000 @ $7,56$227K · 2026-06-24
- Chief Medical Officer · Common StockSold 30 000 @ $21,42$643K · 2026-06-24
- Chief Scientific Officer · Common StockOther 3 000 @ $6,14$18K · 2026-06-23
- Chief Medical Officer · Common StockOther 6 000 @ $7,56$45K · 2026-06-23
- Chief Medical Officer · Common StockSold 11 845 @ $20,22$240K · 2026-06-23
- Chief Operating Officer · Common StockOther 2 175 @ $3,98$9K · 2026-06-23
- Chief Operating Officer · Common StockSold 2 175 @ $20,00$44K · 2026-06-23
- Chief Scientific Officer · Common StockSold 3 000 @ $20,00$60K · 2026-06-23
- Chief Scientific Officer · Common StockOther 3 000 @ $6,14$18K · 2026-06-17
- Chief Operating Officer · Common StockOther 2 176 @ $3,98$9K · 2026-06-17
- Chief Operating Officer · Common StockSold 2 176 @ $19,00$41K · 2026-06-17
Short positioning
17.2Mshares short-7.7% vs prior
13.08days to cover
30.8%short of daily vol
778fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
GLUE.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Current liabilities (annual): USD 64.21MUnknown
- Current assets (annual): USD 393.19MUnknown
- Shares outstanding (annual): 65.54MUnknown
- Operating cash flow (annual): USD -22.8MUnknown
- Operating income (annual): USD -54.21MUnknown
- Capex (annual): USD 4.7MUnknown
- R&D expense (annual): USD 141.5MUnknown
- Total liabilities (annual): USD 215.6MUnknown
- Pre-tax income (annual): USD -39.72MUnknown
- Total operating expenses (annual): USD 177.88MUnknown
- Total assets (annual): USD 448.66MUnknown
- Net income (annual): USD -38.6MUnknown
- Cash & equivalents (annual): USD 129.88MUnknown
- Shareholders' equity (annual): USD 233.06MUnknown
- Total operating expenses (annual): USD 156.73MUnknown
- Operating income (annual): USD -81.11MUnknown
- Operating cash flow (annual): USD 42MUnknown
- Capex (annual): USD 3.99MUnknown
- Total assets (annual): USD 438.73MUnknown
- Cash & equivalents (annual): USD 224.25MUnknown
- Net income (annual): USD -72.7MUnknown
- Current liabilities (annual): USD 156.95MUnknown
- Shareholders' equity (annual): USD 222.94MUnknown
- R&D expense (annual): USD 121.56MUnknown
Showing 24 of 28 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-16INSIDERWarmuth Markus sold 9.5k sh — Director, President & CEO ~$220k
2026-07-15INSIDERChampoux Jennifer transacted 4.4k sh — Chief Operating Officer ~$17k
2026-07-15INSIDERChampoux Jennifer sold 4.4k sh — Chief Operating Officer ~$102k
2026-07-15INSIDERChampoux Jennifer disposed of 4.4k sh Stock Option (Right to Buy) — Chief Operating Officer
2026-07-06INSIDERTownson Sharon sold 400 sh — Chief Scientific Officer ~$10k
2026-07-06INSIDERTownson Sharon sold 5.6k sh — Chief Scientific Officer ~$130k
2026-07-06INSIDERTownson Sharon transacted 6.0k sh — Chief Scientific Officer ~$37k
2026-07-06INSIDERTownson Sharon disposed of 6.0k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-07-01INSIDERBehbahani Ali transacted 1.00M sh — Director
2026-07-01INSIDERBehbahani Ali transacted 15.0k sh — Director
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
2026-06-30INSIDERJanku Filip transacted 5.4k sh — Chief Medical Officer ~$73k
2026-06-30INSIDERJanku Filip sold 5.4k sh — Chief Medical Officer ~$132k
2026-06-30INSIDERJanku Filip disposed of 5.4k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-06-29INSIDERManning Anthony M. transacted 10.0k sh — Director ~$42k
2026-06-29INSIDERJanku Filip transacted 6.0k sh — Chief Medical Officer ~$45k
2026-06-29INSIDERJanku Filip sold 6.0k sh — Chief Medical Officer ~$138k
2026-06-29INSIDERManning Anthony M. sold 10.0k sh — Director ~$231k
2026-06-29INSIDERManning Anthony M. disposed of 10.0k sh Stock Option (Right to Buy) — Director
2026-06-29INSIDERJanku Filip disposed of 6.0k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-06-24 00:00 UTCINSIDER27 insider transactions — 2026-06 · net sell $864k 13 derivative
2026-06-24 00:00 UTCINSIDER27 insider transactions — 2026-06 · net sell $864k 13 derivative
2026-06-24INSIDERJanku Filip transacted 30.0k sh — Chief Medical Officer ~$227k
2026-06-24INSIDERJanku Filip sold 30.0k sh — Chief Medical Officer ~$643k
2026-06-24INSIDERJanku Filip disposed of 30.0k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-06-23INSIDERTownson Sharon transacted 3.0k sh — Chief Scientific Officer ~$18k
2026-06-23INSIDERJanku Filip transacted 6.0k sh — Chief Medical Officer ~$45k
2026-06-23INSIDERJanku Filip sold 11.8k sh — Chief Medical Officer ~$240k
2026-06-23INSIDERChampoux Jennifer transacted 2.2k sh — Chief Operating Officer ~$9k
2026-06-23INSIDERChampoux Jennifer sold 2.2k sh — Chief Operating Officer ~$44k
2026-06-23INSIDERTownson Sharon sold 3.0k sh — Chief Scientific Officer ~$60k
2026-06-23INSIDERChampoux Jennifer disposed of 2.2k sh Stock Option (Right to Buy) — Chief Operating Officer
2026-06-23INSIDERJanku Filip disposed of 6.0k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-06-23INSIDERTownson Sharon disposed of 3.0k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-06-17INSIDERTownson Sharon transacted 3.0k sh — Chief Scientific Officer ~$18k
2026-06-17INSIDERChampoux Jennifer transacted 2.2k sh — Chief Operating Officer ~$9k
2026-06-17INSIDERChampoux Jennifer sold 2.2k sh — Chief Operating Officer ~$41k
2026-06-17INSIDERTownson Sharon disposed of 3.0k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-06-17INSIDERChampoux Jennifer disposed of 2.2k sh Stock Option (Right to Buy) — Chief Operating Officer
Showing the 40 most recent of 62 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage